epanutin infatabs 50mg chewable tablets
upjohn eesv - phenytoin - chewable tablet - 50 milligram(s) - hydantoin derivatives; phenytoin
trazodone hydrochloride- trazodone hydrochloride tablet, film coated
bryant ranch prepack - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - trazodone hydrochloride 50 mg - trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (mdd) in adults. trazodone hydrochloride tablets are contraindicated in: - patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (maois), including maois such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see warnings and precautions (5.2), drug interactions (7.1)]. patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (maois), including maois such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see warnings and precautions (5.2), drug interactions (7.1)]. teratogenic effects pregnancy category c trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in the rat when given at dose levels approximately 6 to 9 times the maximum recommended human dose (mrhd) of 400 mg/day on mg/m2 in adolescents. there was also an incr
trazodone hydrochloride tablet
direct rx - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - trazodone hydrochloride 100 mg - 1 indications and usage trazodone hydrochloride tablets usp are indicated for the treatment of major depressive disorder (mdd) in adults. the efficacy of trazodone hydrochloride tablets usp has been established in trials with the immediate release formulation of trazodone [see clinical studies (14)]. none. 8.1 pregnancy teratogenic effects pregnancy category c trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in two studies using the rat when given at dose levels approximately 30 to 50 times the proposed maximum human dose. there was also an increase in congenital anomalies in one of three rabbit studies at approximately 15 to 50 times the maximum human dose. there are no adequate and well-controlled studies in pregnant women. trazodone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 8.3 nursing mothers trazodone and/or its metabolites have been found in the milk of lactating
trazodone hydrochloride- trazodone hydrochloride tablet
unit dose services - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - trazodone hydrochloride 100 mg - trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (mdd) in adults. the efficacy of trazodone hydrochloride tablets has been established in trials with the immediate release formulation of trazodone [see clinical studies (14)]. none. teratogenic effects pregnancy category c trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in two studies using the rat when given at dose levels approximately 30 to 50 times the proposed maximum human dose. there was also an increase in congenital anomalies in one of three rabbit studies at approximately 15 to 50 times the maximum human dose. there are no adequate and well-controlled studies in pregnant women. trazodone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. trazodone and/or its metabolites have been found in the milk of lactating rats, suggesting that the drug may be secreted in human milk. caut
trazodone hydrochloride tablet
nucare pharmaceuticals,inc. - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - trazodone hydrochloride 50 mg - trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (mdd) in adults. the efficacy of trazodone hydrochloride tablets has been established in trials with the immediate release formulation of trazodone [see clinical studies ( 14)]. none. teratogenic effects pregnancy category c trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in two studies using the rat when given at dose levels approximately 30 to 50 times the proposed maximum human dose. there was also an increase in congenital anomalies in one of three rabbit studies at approximately 15 to 50 times the maximum human dose. there are no adequate and well-controlled studies in pregnant women. trazodone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. trazodone and/or its metabolites have been found in the milk of lactating rats, suggesting that the drug may be
lamitan lamotrigine 200 mg dispersible/chewable tablet blister pack
arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 200 mg - tablet, chewable - excipient ingredients: calcium carbonate; microcrystalline cellulose; crospovidone; maize starch; purified talc; saccharin sodium; sodium stearylfumarate; colloidal anhydrous silica; sorbitol; flavour - lamotrigine is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.
lamitan lamotrigine 100 mg dispersible/chewable tablet blister pack
arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 100 mg - tablet, chewable - excipient ingredients: calcium carbonate; microcrystalline cellulose; crospovidone; maize starch; purified talc; saccharin sodium; sodium stearylfumarate; colloidal anhydrous silica; sorbitol; flavour - lamotrigine is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.
lamitan lamotrigine 50 mg dispersible/chewable tablet blister pack
arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 50 mg - tablet, chewable - excipient ingredients: calcium carbonate; microcrystalline cellulose; crospovidone; maize starch; purified talc; saccharin sodium; sodium stearylfumarate; colloidal anhydrous silica; sorbitol; flavour - lamotrigine is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.
apx-lamotrigine lamotrigine 200 mg dispersible/chewable tablet blister pack
arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 200 mg - tablet, chewable - excipient ingredients: calcium carbonate; microcrystalline cellulose; crospovidone; maize starch; purified talc; saccharin sodium; sodium stearylfumarate; colloidal anhydrous silica; sorbitol; flavour - lamotrigine is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.
apx-lamotrigine lamotrigine 100 mg dispersible/chewable tablet blister pack
arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 100 mg - tablet, chewable - excipient ingredients: calcium carbonate; microcrystalline cellulose; crospovidone; maize starch; purified talc; saccharin sodium; sodium stearylfumarate; colloidal anhydrous silica; sorbitol; flavour - lamotrigine is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.